Hangzhou Zede Pharma-Tech Co., Ltd. Report issue

For profit Phase 2
Founded: Hangzhou China (2013)

Organization Overview

First Clinical Trial
2018
NCT03673085
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hangzhou Zede Pharma-Tech Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

cn128 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Iron Overload (Phase 2)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1